Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Hold” by Brokerages

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been assigned an average recommendation of “Hold” from the five analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $14.00.

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. The Goldman Sachs Group lowered their target price on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research note on Wednesday, July 17th. StockNews.com initiated coverage on Atara Biotherapeutics in a research note on Wednesday, June 26th. They issued a “hold” rating on the stock. Canaccord Genuity Group restated a “buy” rating and set a $13.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, August 13th. Finally, Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and dropped their price objective for the stock from $25.00 to $18.00 in a report on Friday, August 16th.

Institutional Trading of Atara Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Atara Biotherapeutics during the second quarter worth $53,000. Cubist Systematic Strategies LLC bought a new stake in shares of Atara Biotherapeutics during the 2nd quarter valued at about $79,000. Delap Wealth Advisory LLC acquired a new stake in Atara Biotherapeutics during the first quarter worth about $29,000. BNP Paribas Financial Markets raised its stake in Atara Biotherapeutics by 29.3% during the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 86,842 shares during the period. Finally, Redmile Group LLC lifted its holdings in Atara Biotherapeutics by 1.7% in the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock worth $6,429,000 after acquiring an additional 156,863 shares during the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Stock Performance

ATRA stock opened at $8.08 on Friday. The firm has a market cap of $38.90 million, a P/E ratio of -0.15 and a beta of 0.50. Atara Biotherapeutics has a 1 year low of $4.96 and a 1 year high of $45.75. The stock has a 50-day simple moving average of $8.26 and a 200-day simple moving average of $12.21.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($1.54). The business had revenue of $28.64 million for the quarter, compared to the consensus estimate of $48.30 million. On average, equities research analysts predict that Atara Biotherapeutics will post -12.09 EPS for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.